---
title: "Sell Rating Maintained on Clinical and Commercial Uncertainty; $9 Price Target Reaffirmed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289805829.md"
description: "Goldman Sachs analyst Salveen Richter maintained a Sell rating on Intellia Therapeutics with a $9 price target. The decision reflects clinical and commercial uncertainties, including a delayed approval timeline for lonvo-z until H1 2027, competitive positioning challenges in the HAE market, and execution risks in the broader CRISPR pipeline."
datetime: "2026-06-15T15:15:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289805829.md)
  - [en](https://longbridge.com/en/news/289805829.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289805829.md)
generator: "portal-rs"
---

# Sell Rating Maintained on Clinical and Commercial Uncertainty; $9 Price Target Reaffirmed

Goldman Sachs analyst Salveen Richter maintained a Sell rating on Intellia Therapeutics yesterday and set a price target of $9.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Salveen Richter has given his Sell rating due to a combination of factors related to both clinical and commercial considerations. While the latest Phase 3 data for lonvo-z in hereditary angioedema show robust reductions in attack rates and meaningful quality-of-life improvements, the approval timeline extends out to an anticipated decision in the first half of 2027, limiting near- to medium-term revenue contribution.

Richter also highlights uncertainty around how lonvo-z will be positioned in an already competitive HAE market, where some physicians and patients may favor established chronic therapies with well-characterized long-term safety over an irreversible gene-editing approach. In addition, the company’s broader CRISPR pipeline, including the nex-z program in transthyretin amyloidosis, faces timeline and execution risks, particularly around large, ongoing Phase 3 studies, which contributes to a more cautious stance and supports maintaining the unchanged $9 price target alongside the Sell rating.

### Related Stocks

- [NTLA.US](https://longbridge.com/en/quote/NTLA.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [Intellia Q2 2026 Earnings: Lonvo-z Moves Toward a BLA](https://longbridge.com/en/news/295103160.md)
- [Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing](https://longbridge.com/en/news/284477682.md)
- [BUZZ-Street View: Target keeps giving shoppers a reason to come back](https://longbridge.com/en/news/296472324.md)
- [Oil hits three-week high on uncertainty over Hormuz](https://longbridge.com/en/news/296355084.md)
- [Oxford Nanopore Technologies PLC (ONT) Receives a Buy from Barclays](https://longbridge.com/en/news/296448100.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**